Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients ...

Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable ...

In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival ...

Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but nearly a third of patients can't tolerate ...

Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report.

The standard treatment for head and neck cancer, cisplatin, can’t be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: cetuximab, a ...

Bangalore: AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from ...

Olaparib in combination with Durvalumab is indicated for the maintenance treatment of adult patients with advanced or ...

AstraZeneca Pharma India has received regulatory approval to import and distribute Lynparza (Olaparib) tablets in 100mg and ...